Embeline™ Family of Products

The following Embeline™ formulations are available for licensing: Embeline™ E Cream, Embeline™ Ointment, Embeline™ Gel, Embeline™ Cream, and Embeline™ Solution.

Offer available for: licensing

Pharmaceutical form and dosage: Treatment should be limited to 2 consecutive weeks. Cream

Type:

- Generics
- FP (finished products)
- Prescription drugs (Rx)

Therapeutic target:

- Dermatology

Action: For the treatment of:
- Moderate to severe plaque-type psoriasis: use up to four weeks
- Dry, scaly dermatoses
- Hand eczema
- Contact dermatitis

Full Description:
Embeline™ formulations contain clobetasol propionate 0.05%, a super-high potency cortisteroid providing anti-inflammatory, anti-pruitic, and vasoconstrictive properties to the skin. The formulations are generic equivalents to the FDA referenced drug Temovate.

Embeline™ E Cream contains clobetasol propionate 0.05% cream-emollient. Available in 15, 30, and 60 gram tubes.

Embeline™ Ointment contains clobetasol propionate 0.05% ointment. Available in 15, 30, 45, and 60 gram tubes.

Embeline™ Gel contains clobetasol propionate 0.05% gel. Available in 15, 30, and 60 gram tubes.

Embeline™ Cream contains clobetasol propionate 0.05% cream. Available in 15, 30, 45, and 60 gram tubes.

Embeline™ Solution contains clobetasol propionate 0.05% topical solution. Available in 25 and 50 milliliter bottles.

Availability and Market information:

Status:

Market(s) and Registration Info: (date: concerns Marketing Authorization)
- United States of America

Market information
First on the market in: United States of America

Other Market Info: All (5) Embeline™ formulations are available for licensing and distribution outside the United States and Canada.

  Contact for this offer: Jay Nisbet